Inflammation is a non-specific response of the organism to injury, infection, or other stimulation, characterized by the activation, migration, and extravasation of inflammatory cells, along with local vascular changes (Medzhitov, 2010). Inflammatory cells play a central role in this process, with their extravasation serving as a critical hallmark of inflammation. These cells include leukocytes (mast cells), granulocytes (eosinophils), and monocytes (macrophages), among others (Abdulkhaleq et al., 2018). The pathway diagram in Figure 1 illustrates the involvement of inflammatory cells in the progression of intestinal fibrosis.

Cytokines are a diverse group of proteins that play a critical role in cell signaling and immune regulation (Wu et al., 2023). Inflammation is a fundamental pathological process by the tissue’s defensive response to various damaging stimulations (Schmitt et al., 2019). The chemical factors that mediate these inflammatory reactions are referred to as chemical or inflammatory mediators (Khan et al., 2023). Figure 2 provides a comprehensive overview of the mechanisms by which cytokines contribute to the progression of intestinal fibrosis.

The pathogenesis of intestinal fibrosis in IBD remains incompletely understood, but there is growing recognition of the significant role played by the microbiota and its metabolites (Bernardi et al., 2024). Studies have highlighted the involvement of the adherent-invasive Escherichia coli (AIEC) strain LF82, which can stably colonize the intestine and enhance the expression of the IL-33 receptor ST2 in intestinal epithelial cells through flagellin, thereby promoting significant fibrosis (Imai et al., 2019). Targeting AIEC and its downstream IL-33-ST2 signaling pathway presents a promising therapeutic strategy for managing intestinal fibrosis. Additionally, it has been confirmed that the AIEC strain LF82 induces collagen deposition and upregulates pro-fibrotic genes in human intestinal epithelial cells (IECs). This strain also amplifies TGF-β1-induced EMT and myofibroblast activation, exerting a pro-fibrotic effect in the intestine (Chokr et al., 2021). Furthermore, the gut microbiota has been shown to exacerbate colitis by promoting the ubiquitination of myeloid cells and the accumulation of the innate immune receptor STING (Larabi et al., 2020). Another study discovered that CD-associated AIEC suppresses the expression of let-7b in exosomes derived from IECs, which in turn modulates macrophage polarization, further exacerbating intestinal fibrosis (Xu et al., 2023).

In contrast, some microbial populations have been identified as having potential therapeutic effects in alleviating fibrosis. For example, a study demonstrated that invasive Lactococcus lactis (NCDO2118 FnBPA⁺) carrying the Mycobacterium leprae Hsp65 antigen (pXYCYT: Hsp65) mitigated TNBS-induced colitis and fibrosis (da Cunha et al., 2020). Furthermore, the soluble fraction of the multi-strain probiotic Vivomixx^® was shown to reduce fibrosis by downregulating the expression of collagen I and α-SMA via the TGF-β1/Smad signaling pathway (Lombardi et al., 2021). Notably, a 2021 study published in Nature Medicine reported that engineered yeast probiotics expressing the human P2Y2 purinergic receptor exhibited a 1000-fold increased sensitivity to extracellular adenosine triphosphate (eATP). This sensitivity, coupled with the secretion of the ATP-degrading enzyme apyrase, allowed the yeast to sense and respond to inflammation-inducing eATP, thereby suppressing intestinal inflammation, reducing fibrosis, and alleviating microbial dysbiosis in an IBD mouse model (Scott et al., 2021). These findings underscore the complex interplay between the microbiota and intestinal fibrosis, highlighting both detrimental and therapeutic microbial interactions that may be harnessed for future treatment strategies.

MSCs are multipotent stem cells characterized by their self-renewal capacity and potential for multilineage differentiation (Fu et al., 2019). Research has demonstrated that MSCs derived from perinatal tissues, including umbilical cords and placenta, can reduce fibrosis when applied to human primary intestinal myofibroblasts (HIMF) (Choi et al., 2019). The use of the small molecule inhibitor CCG-100602, which targets the Serum Response Factor (SRF) and its transcriptional coactivator Myocardin-Related Transcription Factor-A (MRTF-A), has further elucidated that the development of fibrosis is associated with the inhibition of the MRTF-A/SRF signaling pathway (Figure 3) (Choi et al., 2019).

In addition to perinatal MSCs, bone marrow-derived mesenchymal stem cells have also been explored for their potential in the treatment of IBD, although opinions regarding their efficacy remain divided. While several studies have highlighted the anti-inflammatory properties of bone marrow-derived MSCs (Goncalves Fda et al., 2014; Gonzalez et al., 2009; He et al., 2012), others have reported conflicting results (Duijvestein et al., 2011; Nam et al., 2015). Nevertheless, there is a broader consensus regarding the efficacy of MSCs in managing fibrosis (Figure 3). For instance, prophylactic administration of MSCs has been shown to inhibit fibrotic tissue accumulation, reduce fibronectin expression, and attenuate EMT. Additionally, therapeutic MSC application has demonstrated the ability to reverse established intestinal fibrosis and diminish EMT (Lian et al., 2018).

Further investigations have examined the role of MSC-derived exosomes (MSC-Exos) in treating IBD. One study revealed that systemic administration of human bone marrow-derived MSC exosomes targeting colonic macrophages significantly alleviated colitis in an IBD mouse model (Liu et al., 2019). Conversely, another study indicated that MSCs and their secreted extracellular vesicles (EVs) exert differential effects on experimental colitis. Bone marrow-derived MSCs were cultured under standard conditions (naïve, nMSCs) or preconditioned with IL-1β, IL-6, and TNF-α (induced, iMSCs), revealing that treatment with induced MSC-derived EVs resulted in reduced fibrosis, decreased angiogenesis, increased expression of Mucin 5ac, polarized intestinal macrophages, and a favorable shift in the Treg/Teff cells ratio in the intestinal lymph nodes (Tolomeo et al., 2021).

Moreover, human adipose-derived MSC (hADSCs), when preconditioned with IFN-γ and Kynurenic acid, have been shown to effectively ameliorate TNBS-induced colitis and colonic fibrosis. These hADSCs enhanced the indoleamine 2,3-dioxygenase 1 (IDO-1) signaling pathway, significantly inhibiting ECM deposition and EMT, while promoting the polarization of macrophages towards an anti-inflammatory M2 phenotype (Ye et al., 2022). These findings highlight the therapeutic potential of MSCs and their secreted products in modulating fibrosis and inflammation in IBD, warranting further exploration in clinical settings.

Pioglitazone and Elafibranor, both Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) agonists, have advanced to Phase III clinical trials for the treatment of Non-Alcoholic Steatohepatitis (NASH), underscoring the relevance of PPAR-γ in fibrotic processes across various organs (Zhang et al., 2009). PPAR-γ is recognized for its role as a natural protective agent against fibrosis, modulating both inflammatory and fibrotic pathways. Notably, a study demonstrated that co-incubation of TGF-β1 with PPAR-γ agonists, such as rosiglitazone or pioglitazone, resulted in a reduction in TGF-β1-induced expression of procollagen I, Fibronectin, and α-SMA. This downregulation of key fibrotic markers occurred through the inhibition of AKT and Smad2 phosphorylation, independent of the PPAR-γ pathway, highlighting a potential non-receptor-mediated mechanism of action (Koo et al., 2017). In addition to these established PPAR-γ agonists, a recent study has identified GED-0507-34, a novel PPAR-γ modulator, which has demonstrated antifibrotic effects in IEC cells induced by TGF-β1. GED-0507-34 was shown to significantly reduce the expression of TGF-β and ACTA1 in primary cultured intestinal myofibroblasts derived from UC patients, further supporting the therapeutic potential of PPAR-γ modulation in intestinal fibrosis (Speca et al., 2016). A comprehensive review of the anti-inflammatory and antifibrotic properties of PPAR-γ highlighted its multifaceted role in regulating the production of pro-inflammatory cytokines and interfering with profibrotic molecules such as Platelet-Derived Growth Factor (PDGF) and TGF-β (Pompili et al., 2023; Vetuschi et al., 2018). These findings underscore PPAR-γ as a critical target for the development of therapeutic strategies aimed at modulating both inflammatory and fibrotic pathways in diseases like IBD and NASH.

Elafin, a prototypical member of the WFDC (WAP [whey acidic protein] four-disulfide core) family of proteins, was initially characterized as a protease inhibitor, but further research has revealed its broader biological activities (Scott et al., 2011). Notably, studies have demonstrated that Elafin can reverse collagen synthesis in human intestinal tissues and myofibroblasts that have been preconditioned with exosomes derived from the serum of CD patients, highlighting its potential as an anti-fibrotic therapeutic (Xie et al., 2022).

Adamdec1, a member of the ADAM (A Disintegrin And Metalloproteinase) metalloproteinase family, has been shown to play a pivotal role in regulating ECM remodeling, intestinal healing, and inflammation (Lambrecht et al., 2018). Research has established that the deficiency of Adamdec1 accelerates ECM accumulation and disrupts tissue architecture, thereby contributing to impaired tissue repair and exacerbating fibrosis (Jasso et al., 2022).

The small molecule inhibitor AC-73 specifically targets CD147 dimerization, effectively blocking CD147’s action in vivo (Fu et al., 2016). CD147, also known as ECM metalloproteinase inducer (EMMPRIN), is a glycosylated transmembrane protein involved in ECM remodeling and regulation of wound healing, inflammatory diseases, and cancers (Landras et al., 2019). A study revealed that AC-73, by inhibiting CD147, effectively reduces intestinal fibrosis in a TNBS-induced chronic colitis model. This effect was mediated through suppression of the ERK1/2 and STAT3 signaling pathways, alongside induction of autophagy, highlighting CD147 as a potential therapeutic target for intestinal fibrosis (Butera et al., 2022).

Among the NADPH oxidase (NOX) family of enzymes, NOX4 is closely linked to tissue fibrosis, though its precise role in the fibrosis process remains controversial (Li Z.M. et al., 2021). Nevertheless, NOX4 has been implicated in modulating DSS-induced intestinal inflammation and fibrosis, with NOX4 deficiency exacerbating both inflammation and fibrosis, thereby hindering the recovery process (Lee et al., 2023).

Proteomic analysis of the decellularized gut has identified milk fat globule-epidermal growth factor 8(MFGE8) as a unique ECM protein in CD. MFGE8 was found to exert anti-fibrotic properties through integrin αvβ5 and focal adhesion kinase (FAK) in human intestinal myofibroblasts (HIMF), presenting a potential therapeutic pathway for mitigating fibrosis (Lin et al., 2024).

In a 2019 study, mTOR inhibitors, such as rapamycin, were shown to suppress IL-23 and IL-22 expression in TNBS-induced fibrotic mice, alleviating intestinal fibrosis. Further investigations revealed that deletion of the autophagy gene ATG7 increased IL-22 expression and exacerbated fibrosis. Additionally, inducing intestinal fibrosis with IL-22 in RAG^−/− mice demonstrated that depletion of innate lymphoid cells (ILCs) could mitigate fibrosis, suggesting that the pro-fibrotic process may occur independently of T and B cells (Mathur et al., 2019).

As clinical trials and experimental research on intestinal fibrosis continue to progress, an increasing array of therapeutic targets is emerging. These findings provide valuable insights into potential treatments for fibrosis in inflammatory bowel diseases, offering hope for more effective clinical management in the future.

Currently, there are no medications specifically targeting advanced fibrosis have been approved for clinical use (Mignini et al., 2024). However, Pirfenidone (5-methyl-N-phenyl-2-(1H)-pyridone, PFD) has emerged as a promising antifibrotic agent, demonstrating significant efficacy in both clinical trials and experimental animal studies (Duan et al., 2015; Rodriguez-Castellanos et al., 2015; Takeda et al., 2014). Preclinical investigations have shown that Pirfenidone, administered either orally or via enema to WT mice, effectively inhibits the activation of TGF-β1-related Smad and MAPK pathways both in vivo and in vitro. These findings suggest that Pirfenidone has a multifaceted mechanism of action in fibrotic processes (Li et al., 2016a; Li et al., 2016b).

Furthermore, studies have highlighted the role of the TRPA1 gene in fibrotic progression. Notably, both steroids (such as prednisolone) and Pirfenidone were found to reduce calcium influx in intestinal myofibroblast cell lines (InMyoFibs), leading to decreased expression of key fibrotic markers, such as HSP47, collagen I, and α-SMA. This effect was antagonized by the selective TRPA1 pathway blocker HC-030031, underscoring the involvement of TRPA1 in the fibrotic response (Kurahara et al., 2018). Increased expression of TRPA1 has been observed in the narrowed intestinal segments of CD patients, with cells positive for both TRPA1 and HSP47 concentrated in these constricted regions, both in human tissue and in TNBS-treated mice (Kurahara et al., 2018).

In additional experimental models, Pirfenidone has been shown to reduce fibrosis by inhibiting collagen deposition. In an ectopic small intestine model, treatment with Pirfenidone resulted in a reduction in collagen layer thickness and a decrease in the expression of TGF-β1 and MMP9, leading to a reduction in fibrosis (Meier et al., 2016). Moreover, Pirfenidone has been demonstrated to prevent radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation, as well as suppressing the TGF-β1/Smad/CTGF signaling pathway (Sun Y.W. et al., 2018b). A similar study reported that Pirfenidone inhibits the proliferation and differentiation of primary small intestinal myofibroblasts (RIFs) in rats, through the suppression of the TGF-β1/Smad/CTGF signaling pathway, ultimately preventing fibrosis and reducing collagen deposition (Sun Y. W. et al., 2018a). Additionally, Pirfenidone has been shown to inhibit the proliferation and apoptosis of human intestinal fibroblasts (HIFs) induced by TGF-β1, via modulation of the Smad and PI3K/AKT signaling pathways (Sun Y. et al., 2018). Another study revealed that Pirfenidone suppresses HIF proliferation and collagen I production through the TGF-β1/Mtor/p70S6K signaling pathway (Cui et al., 2020). These findings collectively support the potential of Pirfenidone as an effective therapeutic agent for the treatment of intestinal fibrosis, providing insights into its mechanism of action and therapeutic promise in managing fibrosis-related conditions in IBD.

Angiotensin II (Ang II), the primary effector molecule of the renin-angiotensin system (RAS), plays a critical role in regulating blood pressure, electrolyte balance, and fluid homeostasis. In addition to its hemodynamic effects, Ang II functions as a potent pro-inflammatory mediator, promoting tissue inflammation through the upregulation of monocyte chemoattractant protein-1 (MCP-1) and other pro-inflammatory cytokines (Shi et al., 2016). Ang II exerts its biological effects primarily through binding Ang II type 1 receptor (AT1R), which is involved in various inflammatory and fibrotic processes. Angiotensin II receptor blockers (ARBs), such as Losartan and Irbesartan, have been investigated for their potential anti-fibrotic effects in inflammatory conditions. Losartan, in particular, has been shown to exert beneficial effects in the context of chronic colitis, demonstrating anti-fibrotic properties by reducing inflammation and modulating fibrotic pathways (Wengrower et al., 2012). More recent studies have highlighted the effects of Irbesartan, which has been shown to inhibit the production of MCP-1 and reduce the accumulation of Ly6C⁺CCR2⁺ monocytes and myofibroblasts in inflamed colonic tissue. Furthermore, Irbesartan downregulates the expression of key fibrotic markers, including collagen I and matrix metalloproteinase-9 (MMP9), thereby impeding the progression of intestinal fibrosis (Hachiya et al., 2021). These findings suggest that ARBs, particularly Irbesartan, may offer a promising therapeutic strategy for mitigating inflammation and fibrosis in conditions such as IBD.

Recent studies have identified the unique efficacy of TCM and its bioactive metabolites in treating intestinal disorders, including intestinal fibrosis (Yang et al., 2021). One such example is Daikenchuto (DKT), a traditional Chinese herbal formula widely used in the management of gastrointestinal disorders (Katsuno et al., 2015). Research has demonstrated that oral administration of DKT alleviates intestinal fibrosis by reducing the expression of HSP47 protein and collagen content in the intestines (Inoue et al., 2011). Further investigation into the molecular mechanisms of DKT revealed its potential to modulate the Transient Receptor Potential Ankyrin 1 (TRPA1) pathway in intestinal myofibroblasts. TRPA1 knockout mice exhibited more severe inflammation and fibrosis, while DKT administration attenuated these fibrotic changes in WT mice, suggesting that DKT exerts its antifibrotic effects through activation of the TRPA1 pathway (Hiraishi et al., 2018). Calcium imaging assays revealed that DKT induced intracellular calcium influx in intestinal myofibroblasts (InMyoFibs), an effect that was reversed by the TRPA1 channel blocker HC-030031 (Hiraishi et al., 2018). Another notable TCM formulation, Wu-Mei-Wan, has demonstrated efficacy in ameliorating chronic colitis-associated intestinal fibrosis by inhibiting fibroblast activation (Wu et al., 2020). Additionally, Qingchang Tongluo Decoction (QTF), as validated by network pharmacology analysis, molecular docking, and both in vivo and in vitro experiments, has been shown to alleviate TNBS-induced intestinal fibrosis in mice by inhibiting the TGF-β/Smad/VEGF signaling pathway (Li et al., 2024).

Maggot extract (ME), derived from the larvae of Musca domestica, has been found to upregulate Nuclear Factor Erythroid 2–Related Factor 2 (Nrf2) and downregulate the TGF-β1/Smads pathway, thereby inhibiting intestinal fibrosis. The protective effects of ME were nullified upon inhibition of Nrf2, either by the Nrf2 inhibitor ML385 or siRNA targeting Nrf2, highlighting the role of Nrf2 in mediating its antifibrotic effects (Wang R. et al., 2021).

Total Flavonoids of Abelmoschus manihot (TFA), the main metabolite of the water extract of the traditional botanical drugs A. manihot, have shown significant therapeutic potential in conditions such as nephritis, nephrotic syndrome, and enteritis (Ge et al., 2016; Liu et al., 2017). TFA has been shown to enhance the expression of epithelial markers associated with fibrosis in IEC-6 cells through the TGF-β1 signaling pathway, reduce mesenchymal markers levels, and inactivate both the Smad and Mitogen-Activated Protein Kinase (MAPK) signaling pathways. The therapeutic efficacy of TFA was further augmented when combined with si-Smad and MAPK inhibitors (Yang et al., 2018a). Moreover, animal studies have confirmed that TFA improves intestinal fibrosis in mice by modulating the Th17/Treg cell balance and reducing ECM production (Qiao et al., 2021). These findings suggest that TFA may be a promising therapeutic agent for the treatment of intestinal fibrosis.

Citrate and hydroxycinnamate derivatives from Prunus mume, a common TCM remedy for chronic diarrhea and dysentery, have also shown promise in the management of CD and associated complications (Liu et al., 2023). A study demonstrated that the 40% ethanol fraction of P. mume (MFE40), the active fraction of its alcohol extract, effectively alleviates the inflammatory and fibrotic aspects of CD (Liu Z. et al., 2022). These findings underscore the potential of TCM and its bioactive metabolites as valuable therapeutic options for intestinal fibrosis, providing promising directions for future research and clinical application.

Several studies have identified that specific monomeric metabolites possess notable potential in improving or alleviating fibrosis across various organs. Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a bioactive metabolite extracted from the rhizomes of the Curcuma longa L., is well-known for its antioxidant, anti-inflammatory, antiviral, antiproliferative, and anticancer properties. Furthermore, Curcumin has shown promise in the prevention and treatment of autoimmune diseases, such as CD (Aggarwal and Harikumar, 2009). Previous research has highlighted the antifibrotic effects of curcumin in liver, lung, and cystic fibrosis (Lipecka et al., 2006; Nan et al., 2011; Punithavathi et al., 2000; Yao et al., 2012). Curcumin pre-treatment has been shown to significantly inhibit the expression of TGF-β and α-SMA genes in IEC-6 cells while promoting the expression of E-cadherin and PPAR-γ genes when compared to the positive control, rosiglitazone. Moreover, curcumin’s facilitation of PPAR-γ nuclear translocation can be reversed by the PPAR-γ antagonist GW9662, indicating its involvement in antifibrotic pathways (Xu et al., 2017).

Silybin, a natural polyphenolic flavonoid compound extracted from the fruits and seeds of Silybum marianum (L.) Gaertn., has been extensively applied in the treatment of colorectal cancer and antiproliferative therapies (Li et al., 2008; Ravichandran et al., 2010). Studies have demonstrated that Silybin ameliorates radiation-induced damage in mice by inhibiting the phosphorylation of Smad2/3, leading to a reduction in collagen deposition within the intestines and a decrease in TGF-β in both intestinal and plasma samples (Kim et al., 2017).

Calycosin, a key active metabolite of the traditional Chinese botanical drug Astragalus mongholicus Bunge, has exhibited multiple pharmacological activities and holds potential therapeutic efficacy against pulmonary and renal fibrosis (Chen et al., 2015; Deng et al., 2018; Duan et al., 2017). Compared to the positive control, 5-ASA, Calycosin effectively inhibits the expression of α-SMA and Collagen I in CCD-18Co by suppressing the TGF-β/Smad signaling pathway, further supporting its antifibrotic potential (Liu J. et al., 2019).

Betulinic acid hydroxamate (BHA), a pentacyclic triterpenoid compound, is an oxygen-mimetic derivative of betulinic acid, which has been shown to dose-dependently stimulate the activation of the Hypoxia-Inducible Factor (HIF) pathway in NIH-3T3 myofibroblasts, leading to collagen gel contraction (Prados et al., 2021).

Triptolide (PG490), a principal active metabolite of Tripterygium wilfordii Hook.f., has been recognized for its antifibrotic effects in renal, hepatic, and pulmonary fibrosis (Chong et al., 2011; Krishna et al., 2001; Yuan et al., 2011). Research has demonstrated that treatment with Triptolide can reduce ECM deposition and collagen synthesis, and inhibit the expression of Collagen I, thereby alleviating fibrosis (Tao et al., 2015b).

Cinnamomum cassia extract (CCE), derived from the bark of the Cinnamomum verum J.Presl, contains Cinnamaldehyde (CCA) as its principal compound. CCA exhibits various beneficial biological effects, including the reduction of pro-inflammatory mediators in macrophages and monocytes (Chao et al., 2008). Moreover, both CCA and CCE have been shown to decrease the release of mast cell mediators, such as β-hexosaminidase and leukotriene C4, as well as pro-inflammatory factors like IL-6, KC/C-X-C motif ligand (CXCL) 8, and CCL2 in LPS-activated myofibroblasts, primarily by inhibiting the phosphorylation of I-kB (Hagenlocher et al., 2013; Hagenlocher et al., 2015). CCE treatment has been associated with a reduction in colonic fibrosis and collagen deposition in the colonic tissue of IL-10^−/− mice (Hagenlocher et al., 2017). In another study by the same research group, Nobiletin (3,4,5,6,7,8-hexamethoxyflavone), a polyethoxylated flavonoid compound found in the Citrus reticulata Blanco, was discovered to exhibit effects similar to CCA and CCE. It improves intestinal barrier function in a rat model of colitis and intervenes in the progression of fibrosis (Hagenlocher et al., 2019).

Pterostilbene, a natural stilbene compound in Vaccinium corymbosum L., exhibits anticancer, anti-inflammatory, antifibrotic, and weight-reducing properties (Peng et al., 2022). Studies indicate that pterostilbene inhibits the expression of C/EBP homologous protein, Cyclooxygenase-2, and TGF-β1/Smad2/3, as well as MMP2, in the intestines of high-fat diet-fed (HFD) mice, suggesting its in modulating fibrosis (Fan-Jiang et al., 2021).

Pentoxifylline, a methylxanthine derivative, and its metabolite (1-(5-hydroxyhexyl)-3,7-dimethylxanthine, or metabolite-1, M-1), have been documented in the treatment of inflammation and fibrosis since the 1990s (Wen et al., 2017). Pentoxifylline and M-1 have been shown to reduce colonic inflammation and decrease collagen content, thereby mitigating fibrosis (Peterson et al., 2011). Moreover, combined treatment with Pentoxifylline and Vitamin E has demonstrated antifibrotic effects by inhibiting both Smad-dependent and Smad-independent TGF-β1 downstream signaling pathways, improving intestinal collagen fiber deposition in animal models. This improvement in intestinal collagen fiber deposition was also confirmed at the animal level (Lee, 2022).

Resveratrol (trans-3,5,4'-trihydroxystilbene), a phytoalexin found in berries, peanuts, grapes, and red wine, has been demonstrated to inhibit fibrosis in various organs, including the vasculature, heart, lungs, kidneys, and liver in animal models (Hong et al., 2010; Jing et al., 2010). In colon smooth muscle cells, resveratrol induced cell cycle arrest, increased the proportion of cells in the S phase, decreased collagen I expression, and inhibited TGF-β1-stimulated proliferation and IGF-I-stimulated collagen production, ameliorating intestinal fibrosis (Garcia et al., 2012). Additionally, in a colonic fibrosis model induced by TNBS in male SD rats, resveratrol reversed the increased expression of collagen I and IGF-I and decreased SIRT1 expression, with similar effects observed in vitro (Li et al., 2014).

Asperuloside, an iridoid compound from Galium odoratum (L.) Scop., is known for its anti-tumor, anti-inflammatory, antioxidant, and anti-obesity effects (Shen et al., 2023). Studies have demonstrated that Asperuloside inhibits EMT in colitis-associated cancer by activating the Vitamin D receptor/Smad3 pathway, thereby preventing the progression of EMT (Lu et al., 2022). Shaoyao (Paeonia lactiflora Pall.), a traditional Chinese botanical drug with over 1,000 years of medicinal use, is commonly used for pain, inflammation, and immune disorders (Zhang and Wei, 2020). Paeoniflorin, an active metabolite from Shaoyao, has been shown to effectively ameliorate colonic fibrosis in rats with postinfectious irritable bowel syndrome by inhibiting the Leptin/Leptin Receptor b (LepRb) signaling pathway (Tian et al., 2022).

These findings underscore the potential of various monomeric metabolites derived from both traditional and modern sources as promising therapeutic agents for the treatment of intestinal fibrosis. Their multifaceted mechanisms of action highlight the importance of further investigation into these bioactive metabolites for the development of effective fibrotic disease therapies.

Acupuncture, a cornerstone of TCM, has long been recognized for its therapeutic efficacy in managing various diseases (Zhuang et al., 2013). Recent studies have highlighted the potential of acupuncture-based treatments, such as mild moxibustion and herb-partitioned moxibustion (HPM), in addressing intestinal fibrosis in CD models. Specifically, it has been shown that these therapies can exert significant effects by modulating key signaling pathways involved in fibrotic processes. For example, mild moxibustion and HPM have been found to regulate the phosphorylation of Ras, Raf-1, MEK-1, and extracellular signal-regulated kinases (ERK-1/2) proteins in colonic tissues, contributing to the attenuation of fibrosis (Wang et al., 2013). Furthermore, HPM therapy has been demonstrated to reduce collagen deposition and improve fibrosis scoring in CD rats, likely through the modulation of the RhoA, ROCK1, and phosphorylated Myosin Light Chain (p-MLC) signaling pathways (Zhao et al., 2021). In addition, targeted moxibustion at specific acupoints, including Tianshu (ST25), Qihai (RN6), Zusanli (ST36), and Shangjuxu (ST32), has been shown to downregulate the expression of key fibrotic markers, including TGF-β1, Smad3, and Snail, while simultaneously inhibiting the expression of the mesenchymal marker fibronectin (Shi et al., 2019).These findings suggest that acupuncture, particularly HPM, may offer a valuable therapeutic approach for mitigating intestinal fibrosis, with potential mechanisms linked to the modulation of key molecular pathways involved in fibrosis development.

Many TCM therapies, including individual botanical drug and herbal formulas, have been utilized throughout history to treat intestinal injuries and are believed to hold potential for restoring gut function. This underscores the need for further research to develop targeted anti-fibrotic therapies. In the 1980s, early case reports began to highlight the role of TCM in managing intestinal stenosis, which is considered the final clinical manifestation of intestinal fibrosis (Table 4). For instance, one case described a patient who, following multiple surgeries for intestinal obstruction, experienced recurrent adhesions leading to intestinal stenosis. The combination of DKT and Guizhi Jia Shaoyao Decoction was found to provide superior therapeutic outcomes in patients with cold deficiency syndrome (Author Anonymous, 1987b). Another case involved a female patient with a history of appendicitis, who underwent three surgeries in adulthood due to adhesions, intestinal stenosis, and perforation. After 3 years of treatment with Guizhi Jia Shaoyao Decoction, her symptoms were completely resolved, with no further discomfort (Author Anonymous, 1987a).

Recent clinical studies have continued to explore the efficacy of TCM in treating intestinal fibrosis. Notably, Xu Su and colleagues examined the effects of Sanleng Wan on intestinal fibrosis in patients with CD. Their findings indicated that patients treated with oral Sanleng Wan demonstrated significant improvements in endoscopic fibrosis scores, reduced CDAI scores, and lower levels of platelet count and D-dimer compared to those receiving conventional Biomedicine treatments like azathioprine (2 mg/kg/d) (Xu et al., 2017). Despite these promising results, progress in the use of TCM for intestinal fibrosis remains slower compared to advancements in the treatment of liver and pulmonary fibrosis. In contrast, significant research has been conducted on TCM’s role in treating liver and pulmonary fibrosis, where therapies have shown more rapid clinical application.

For liver fibrosis, TCM formulations with blood-activating and stasis-dispelling properties have been widely studied and applied, offering promising potential for preventing and reversing liver fibrosis. For example, the “Guidelines for Diagnosis and Treatment of Hepatic Fibrosis with Integrated Traditional Chinese and Biomedicine (2019 edition) (Xu et al., 2020), recommend several patented TCM formulations, including Anluo Huaxian Pills (AHP), Fuzheng Huayu Tablets (FZHY), and Fufang Biejia Ruangan Tablets (RGT). Randomized controlled trials have demonstrated the potential of RGT in reversing liver fibrosis in patients with chronic hepatitis B (CHB) or hepatitis B virus (HBV)-related compensated cirrhosis, although it does not prevent liver cancer (Qu et al., 2014). Furthermore, a multicenter trial published in 2022 highlighted the synergistic effects of RGT combined with entecavir (ETV), with patients showing an 8.2% higher rate of liver fibrosis regression after 72 weeks of treatment compared to controls (Rong et al., 2022). A multicenter trial with five hospitals showed that after 48 weeks, FZHY and ETV combination therapy did not differ significantly from the control in virological outcomes but improved biochemical responses and showed trends toward better liver fibrosis in hepatitis B-related cirrhosis patients (Cheng et al., 2022). A double-blind trial with 270 patients found significant histological improvement and reduced liver stiffness after 48 weeks of AHP treatment, with no severe side effects (Miao et al., 2019; Xiao et al., 2022). Another trial involving 802 hepatitis B-related cirrhosis patients found that YQSHD combined with entecavir reduced the annual liver cancer incidence to 1% over 2 years (Wu et al., 2021).

In the field of pulmonary fibrosis, numerous clinical trials have been conducted to explore the efficacy of TCM in managing conditions such as idiopathic pulmonary fibrosis (IPF). One randomized controlled trial involving 60 patients with IPF, characterized by Qi and Yin deficiency, demonstrated that treatment with Mai Men Dong Decoction combined with Pirfenidone for 24 weeks significantly improved pulmonary function and reduced the diffusion capacity for nitric oxide (DLCO) (Gan et al., 2020). Similarly, studies on Qizhukangxian Granules and Kangxianhuanji Granules have shown significant improvements in pulmonary function and symptom management in IPF patients (Guo et al., 2020; Hailong et al., 2022). A multicenter, double-blind trial with 312 IPF patients demonstrated that Jinshui Huanxian Granules (JHG) combined with Pirfenidone reduced acute exacerbations, improved pulmonary function, enhanced quality of life, and delayed disease progression after 52 weeks (Yang, S.G. et al., 2022). Another multicenter trial found that the combination of TCM mixed granules and Pirfenidone significantly improved respiratory function and quality of life in patients with post-COVID-19 pulmonary fibrosis (Lu et al., 2021).

These clinical studies underscore the importance of integrating TCM with synthetic drugs for the treatment of fibrosis across various organs. They also highlight the need for an evidence-based approach to evaluate the clinical efficacy of these integrative therapies. Moving forward, the development of a robust, multidimensional clinical efficacy evaluation system, which includes both TCM syndromes and patient quality of life, will be essential in advancing the treatment of fibrosis, particularly in the context of IBD. Ultimately, these studies may pave the way for a comprehensive treatment strategy that enhances the management of intestinal fibrosis and improves the quality of life for affected patients.

Dietary habits play a significant role in the development and progression of intestinal fibrosis, with salt consumption being a critical factor. Excessive salt intake has been linked to various diseases, including hypertension and cardiovascular disorders (Kotchen et al., 2013). Studies have shown that high dietary salt exacerbates intestinal fibrosis in IBD, with experimental models indicating more severe intestinal inflammation and fibrosis in animals treated with TNBS and additional dietary salt (Amamou et al., 2021). In contrast, dietary interventions such as 4% apple pectin supplementation have been shown to reduce fibrosis markers by increasing short-chain fatty acids (SCFAs) and altering gut microbiota composition (Yang et al., 2017). Similarly, Fermented Rice Bran (FRB) and cottonseed oil have been demonstrated to modulate fibrosis-related pathways, reducing intestinal fibrosis in experimental models (Agista et al., 2021; Park et al., 2019). Additionally, compounds like All-trans retinoic acid (ATRA) and nicotinamide mononucleotide (NMN) have been shown potential to mitigate fibrosis in radiation-induced models, highlighting the role of dietary factors in the modulation of intestinal fibrosis (Leem et al., 2017; Okoshi et al., 2008; Zhao et al., 2023). Furthermore, Aryl Hydrocarbon Receptor (AHR) ligands, such as FICZ, curcumin, and L-kynurenine, have been explored for their anti-fibrotic properties, although some studies report contrasting findings regarding their effectiveness in human colonic fibroblasts (Amamou et al., 2022; Lamas et al., 2018; Lamas et al., 2016).

The vitamin D analog CARD-024 (1-alpha-hydroxyvitamin D5) has been characterized as a compound with minimal hypercalcemic effects, making it a promising candidate for therapeutic use in fibrotic disease (Mehta et al., 2003). In vitro studies have demonstrated that CARD-024 can reverse the fibrotic phenotype induced by TGF-β stimulation in CCD-18Co colonic myofibroblasts, characterized by increased actin stress fibers, maturation, and elevated α-SMA expression, thereby ameliorating intestinal fibrosis (Johnson et al., 2012). Additional research has highlighted that vitamin D supplementation in vitamin D-deficient CD-1 mice resulted in downregulation of ECM production and collagen synthesis, as well as reduced TGF-β1 and Smad3 levels in subepithelial myofibroblasts isolated from mouse colon (SEMF) (Tao et al., 2015a). Furthermore, a reduction in vitamin D Receptor (VDR) levels has been observed in resected tissues and epithelial cells of CD patients, with vitamin D treatment found to restore VDR expression, preventing the accelerated transition of myofibroblasts and inhibiting intestinal fibrosis in an animal model (Gisbert-Ferrándiz et al., 2020). Notably, VDR knockout mice developed more severe intestinal fibrosis, and reduced VDR expression in human colonic myofibroblasts, suggesting that VDR plays a crucial role in the modulation of intestinal fibrosis (Yu et al., 2021). These findings suggest that vitamin D supplementation may serve as a potential strategy for preventing intestinal fibrosis.